Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECI: Neoadjuvant Arterial Embolization Chemotherapy Combined Immune Checkpoint Inhibitor for Locally Advanced Rectal Cancer
NCT05420584Phase 2Unknown
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in rectal cancer, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Imaging Tumor Regression Rate at 3 weeks. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05420584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420584.